Nadroparin calcium

Phase 3Small molecule

Italfarmaco

Nadroparin calcium is one of 61 small molecule programs targeting Hemorrhage. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HemorrhageActive, not recruiting

ThromboembolismActive, not recruiting

ThrombophiliaActive, not recruiting

HemorrhagePreclinical

Active, not recruiting

ThromboembolismPhase 3

Active, not recruiting

ThrombophiliaPhase 3

Active, not recruiting

Competition

Competitive Landscape

137 competitors in Hemorrhage

#DrugCompanyPhaseTrials

Cytotec

Pfizer

Phase 3

3 2

Cyklokapron

AAmring

Phase 3

10 3

Activase

Roche

Phase 3

1 4

Virazole

CConrado Roberto Hoffmann Filho

Phase 3

1 5

Betadine

BBecton, Dickinson and Company

Phase 3

1 6

Glypressin

MMallinckrodt

Phase 3

1 7

Statins

Sanofi

Phase 3

1 8

Epoetin Beta

Ulipristal Acetate

Thyroxine

WWashington University School of Medicine

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thrombophilia1 trial

Heparin for Pregnant Women With Thrombophilia

Unknown status·MMedical University of Vienna·Phase 3·NCT01019655·300 enrolled

Thromboembolism1 trial

Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)

Completed· Italfarmaco logo

Italfarmaco·Phase 3·NCT00951574·1,166 enrolled

Hemorrhage1 trial

The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery

Completed·SShanghai Zhongshan Hospital·N/A·NCT01267305·362 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Nadroparin calcium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nadroparin calcium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nadroparin calcium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Italfarmaco company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Italfarmaco

Nadroparin calcium

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thrombophilia1 trial

Thromboembolism1 trial

Hemorrhage1 trial

References

Drug Info

Quick Facts

Related News